This paper is based on a presentation made by the author at the meetin
g of the American Urological Association's Society for the Study of Im
potence on April 12, 1997. The author addresses the general applicabil
ity of the Federal Trade Commission Act to advertising by so-called im
potence 'treatment mills,' focusing in particular an the Federal Trade
Commission's case in the matter of Genetus Alexandria, Inc., et al.